We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BOEHRINGER CITED FOR UNSUPPORTED EFFICACY CLAIMS FOR MICARDIS
BOEHRINGER CITED FOR UNSUPPORTED EFFICACY CLAIMS FOR MICARDIS
December 2, 2004
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has issued an untitled letter to Boehringer Ingelheim, citing the company for a sales aid promoting its antihypertensive drug, Micardis.